Artiva Biotherapeutics, Inc. — Form 10-Q
Filed August 6, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
Artiva separated Thad Huston effective May 22, 2026, providing 3 months severance ($150K base salary continuation), 9 months COBRA, and 3-month equity acceleration—total cost ~$180K. Simultaneously hired Diego Miralles as President, Head of R&D at $600K base + 45% bonus target, 232,500 options and 77,500 RSUs. Company issued pre-funded common stock purchase warrants (Exhibit 4.3) on May 8, 2026 via underwriting with Jefferies, TD Securities, and Cantor Fitzgerald, though specific share count and exercise price blanks were left unfilled in the filing.
Why this rating
Executive turnover is routine at micro-cap biotech. Huston severance ~1.2% of $15M market cap. Miralles hire at $600K salary is material (~4% annual cost for $15M company) but standard for R&D leadership. Warrant issuance structure is incomplete in filing—critical blanks omit share count and pricing, preventing significance assessment of dilution risk. No concrete capital raise amount disclosed.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.